YOLFTbeta
Crossject

Crossject

ALCJ · PA · Healthcare / Medical Instruments & Supplies

1.32EUR-0.02 (-1.49%)

Price History

Full chart

Market Stats

Previous Close1.34
Open1.30
Day Range1.26 – 1.34
52-Week Range1.19 – 2.70
Volume151.95K
Market Cap78.95M
P/E (TTM)0.00
Forward P/E13.16
EPS-0.19
Dividend Yield0.00%
Beta0.50
50-Day Avg1.43
200-Day Avg1.85

About

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Patrick Alexandre
  • Employees99
  • Headquarters6 Rue Pauline Kergomard, Dijon, France, 21000, France
  • Websitehttps://www.crossject.com

Leadership

  • Mr. Patrick AlexandreCo-Founder, CEO & Chairman of the Executive Board
  • Mr. Lionel SeltzCO & Member of Executive Board
  • Dr. Isabelle LiebschützChief Quality & Regulatory Officer and Member of Executive Board
  • Dr. Olivier Lacombe PH.D.Pharmaceutical Development Director & Member of Executive Board
  • Mr. Didier MorinIndustrial Director & Member of Executive Board
  • Mr. Tony TiptonChief Operating Officer of U.S

Financials

Income Statement

Currency: EUR2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue200.00K650.00K353.50K935.92K1.39M1.59M1.42M3.23M2.44M500.00K4.84M912.00K954.00K145.00K4.12M0
Growth (%)-+225.00%-45.62%+164.76%+48.00%+14.50%-10.30%+127.34%-24.43%-79.54%+868.80%-81.17%+4.61%-84.80%+2737.93%-100.00%
Cost of Revenue2.05M44.08K79.28K921.10K4.06M1.50M1.70M2.26M2.97M10.40M3.95M11.97M14.85M18.50M4.85M22.38M
Gross Profit-1.85M605.92K274.22K14.82K-2.67M89.16K-282.04K975.68K-523.83K-9.90M894.74K-11.06M-13.89M-6.13M-21.89M-22.38M
Gross Margin-926.79%93.22%77.57%1.58%-192.79%5.62%-19.82%30.17%-21.43%-1980.15%18.47%-1213.05%-1456.39%-4231.03%-532.03%-
Operating Expense2.58M2.46M1.69M2.63M2.44M6.06M7.36M9.95M11.49M-776.69K11.79M760.00K-666.00K5.67M-6.66M-10.28M
Operating Income-4.43M-1.85M-1.41M-2.62M-5.11M-5.97M-7.64M-8.98M-12.01M-9.12M-10.89M-11.82M-13.23M-11.80M-15.24M-12.10M
Operating Margin-2215.70%-285.34%-399.98%-279.50%-368.75%-376.58%-537.33%-277.59%-491.49%-1824.81%-224.87%-1296.38%-1386.58%-8137.93%-370.30%-
EBITDA-3.66M-1.01M-681.02K-1.54M-4.23M-5.52M-5.94M-6.36M-9.04M-4.76M-7.13M-7.33M-8.03M-7.30M-9.35M-7.21M
EBITDA Margin-1832.28%-155.90%-192.65%-164.58%-305.12%-347.77%-417.50%-196.73%-370.06%-952.79%-147.24%-804.06%-841.19%-5032.41%-227.10%-
Net Income-4.12M1.55M-925.75K-1.82M-4.34M-5.69M-6.66M-7.61M-10.71M-7.17M-9.84M-10.81M-11.16M-8.64M-12.79M-10.37M
Net Income Margin-2058.76%237.75%-261.88%-194.74%-313.04%-358.57%-468.32%-235.32%-438.26%-1434.74%-203.22%-1184.87%-1169.50%-5957.24%-310.94%-
R&D-1.14M787.00K555.76K2.73M3.63M3.76M4.51M5.17M4.65M5.80M6.06M7.41M9.56M--
R&D as % of Total Revenue-174.77%222.63%59.38%197.43%228.96%264.25%139.38%211.71%929.83%119.70%664.44%776.63%6590.26%--
Interest Expense341.80K318.42K212.42K195.54K36.42K18.89K37.70K17.53K222.64K98.61K408.17K845.00K277.00K497.00K1.43M1.58M
Interest Expense % of Total Revenue170.90%48.99%60.09%20.89%2.63%1.19%2.65%0.54%9.11%19.72%8.43%92.65%29.04%342.76%34.73%-

Balance Sheet

Currency: EUR2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.67M2.89M2.59M5.65M18.37M13.88M14.25M17.72M20.16M24.49M33.59M31.52M32.86M28.64M31.57M30.43M
Total Liabilities11.06M5.04M4.50M4.70M3.89M5.08M7.97M11.63M18.50M21.48M34.72M37.01M30.17M33.91M34.24M35.30M
Total Equity-8.39M-2.15M-1.90M947.65K14.48M8.80M6.28M6.09M1.65M3.01M-1.13M-6.15M2.02M-5.27M-2.67M-4.87M
Cash272.41K352.21K178.36K2.47M10.83M4.57M2.59M2.64M4.76M7.80M8.13M9.83M7.77M2.30M7.04M5.08M
Total Debt3.85M2.22M2.04M1.45M--755.00K2.35M11.95M10.50M21.06M24.35M14.13M19.00M18.35M19.82M
Net Debt3.58M1.87M1.86M-1.01M-10.83M-4.57M-1.84M-1.64M1.72M2.70M12.93M13.50M6.36M16.70M11.32M14.74M

Cash Flow

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-569.06K-964.00K-3.16M-4.80M-4.40M-4.97M-8.02M-5.51M-5.46M-6.08M-5.08M-6.20M-7.96M-6.35M
Investing Cash Flow-790.92K-1.14M-4.77M-1.80M-6.07M-4.25M-3.27M-4.40M-6.10M-6.73M-6.78M-2.64M-3.43M-4.46M
Financing Cash Flow1.19M4.39M16.39M827.00K7.95M9.39M13.30M13.00M11.93M14.52M9.64M3.36M16.13M8.85M
Capital Expenditure790.92K1.14M4.77M1.80M6.07M4.25M3.27M4.40M6.10M6.73M6.78M6.40M3.53M4.50M
Free Cash Flow-1.36M-2.10M-7.93M-6.60M-10.47M-9.22M-11.29M-9.91M-11.56M-12.82M-11.86M-12.60M-11.48M-10.85M
FCF to OCF238.99%217.95%250.81%137.64%237.72%185.40%140.83%179.87%211.61%210.67%233.43%203.26%144.33%170.89%

Earnings

Report DateApr 29, 2016Sep 20, 2016May 5, 2017Nov 27, 2017May 18, 2018Sep 26, 2018Mar 13, 2019Sep 9, 2019Mar 26, 2020Sep 18, 2020Mar 29, 2021Sep 22, 2021Mar 24, 2022Sep 16, 2022Mar 20, 2023Apr 29, 2025Sep 24, 2025Oct 31, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.00--0.000.000.00
EPS Actual-0.32-0.41-0.49-0.38-0.47-0.51-0.38-0.27-0.25-0.26-0.17-0.23-0.19-0.17-0.14-0.130.00-0.10
Surprise------------------
Timing-Pre-market---After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours---

Key Statistics & Ratios

Market Cap78.95M
Enterprise Value96.44M
Trailing P/E0.00
Forward P/E13.16
Price / Sales576.31
Price / Book40.53
EPS-0.19
Book Value-0.093
Revenue (TTM)137.00K
Gross Profit (TTM)-12.18M
EBITDA-14.29M
Profit Margin0.00%
Operating Margin-10853.29%
Return on Equity-1498.24%
Return on Assets-27.76%
Shares Outstanding60.27M
Shares Float51.16M
Beta0.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 10, 2025518:509
  • May 14, 2024917:909
  • Oct 6, 20221223:1216
  • Nov 29, 2018664:643
  • Mar 14, 2017677:667